Is Eli Lilly Stock a Buy? Here’s What the Market Isn’t Pricing in Yet.

view original post

Eli Lilly’s obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics’ dual-formulation obesity …